Tenax Therapeutics, Inc.

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors into whether the Company may have violated the federal securities laws. The investigation comes after a August 10, 2026 disclosure concerning Tenax Therapeutics, Inc.

New York, New York--(Newsfile Corp. - October 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors that purchased or otherwise acquired Tenax securities between November 13, 2023 and August 7, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Tenax and have suffered losses, you may CLICK HERE to contact us.

Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) Director Declan Doogan purchased 53,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 16th. The stock was purchased at an average price of $1.92 per share, with a total value of $101,760.00. Following the purchase, the director directly owned 55,274 shares of

CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief Executive Officer, will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET.